AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

MEDP · NASDAQ · Medical - Diagnostics & Research

Medpace (MEDP)

Runs integrated Phase I–IV trials and laboratory services for drug and device developers.

$630.21

After hours−0.58 (−0.09%)

At close$630.79(+1.06%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	492	498	511	528	533	537	559	603	660	708	707	707
Cost of revenue	359	362	356	374	364	358	380	423	463	503	510	506
Gross profit	133	137	155	154	169	178	178	180	197	205	196	202
	48	49	51	49	57	53	65	54	55	52	55	55
	41	43	44	41	49	45	58	47	48	45	48	48
Selling & marketing	0	0	0	0	0	2	0	0	0	0	0	0
General & administrative	0	0	0	0	0	44	0	0	0	0	0	0
Other expenses	7	7	7	7	8	8	7	7	7	7	7	7
Operating income	85	87	104	105	112	125	114	126	142	153	142	147
	−2	3	9	5	7	9	5	−2	1	4	6	5
Interest income	0	2	4	5	8	8	6	1	2	0	5	−5
Interest expense	0	0	0	0	0	0	0	0	0	0	0	0
Other non-operating income	0	−2	−9	−5	−7	−9	−5	2	−1	−4	−6	6
Income before tax	83	91	113	110	119	134	118	125	143	157	148	152
Income tax expense	13	12	10	22	22	17	4	34	32	22	24	30
Net income from continuing operations	71	78	103	88	96	117	115	90	111	135	124	121
Net income	71	78	103	88	96	117	115	90	111	135	124	121
EPS, basic	$2.30	$2.55	$3.32	$2.85	$3.11	$3.78	$3.77	$3.16	$3.95	$4.78	$4.35	$4.31
EPS, diluted	$2.22	$2.46	$3.20	$2.75	$3.01	$3.67	$3.67	$3.10	$3.87	$4.67	$4.28	$4.25
Weighted average shares, basic	31	31	31	31	31	31	30	29	29	28	28	28
Weighted average shares, diluted	32	32	32	32	32	32	31	30	30	29	29	29
EBITDA	92	96	120	118	126	141	125	132	150	164	154	134
Depreciation & amortization	7	7	7	7	8	8	7	7	7	7	7	−7
EBIT	85	90	113	110	119	134	118	125	143	157	148	141